Legumain-IN-2 

Legumain-IN-2 is a selective legumain inhibitor with a human legumain IC₅₀ of 0.9 nM. Legumain-IN-2 can be used for the research of breast cancer^[1].

Legumain-IN-2 (Compound 7u) potently inhibits recombinant human Legumain with an IC₅₀ of 0.9 nM^[1].
Legumain-IN-2 (30 μM) is highly selective for Legumain, showing minimal to moderate inhibition of other tested cysteine proteases^[1].
Legumain-IN-2 (30 μM; 120 h) reduces cell count by >70% in MCF7 and T47D breast cancer cells, but has no effect on MCF10a and HME-1 normal breast cell viability under the same conditions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

464.51

C₂₅H₂₈N₄O₅

1609690-02-9

NC(C[C@@H](C#N)NC([C@H]1N(CCC1)C(OCC2=CC=C(C3=CC(OCC)=CC=C3)C=C2)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Higgins C, et al. P3 SAR exploration of biphenyl carbamate based Legumain inhibitors. Bioorg Med Chem Lett. 2014;24(11):2521-2524.